Celularity Inc. (CELUW)
- Previous Close
0.0400 - Open
0.0372 - Bid --
- Ask --
- Day's Range
0.0372 - 0.0499 - 52 Week Range
0.0372 - 0.0499 - Volume
690 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8700 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBankin. Its lead therapeutic programs include CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.
www.celularity.comRecent News: CELUW
View MoreCompare To: CELUW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CELUW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-106.77%
Return on Assets (ttm)
-17.42%
Return on Equity (ttm)
-232.51%
Revenue (ttm)
54.22M
Net Income Avi to Common (ttm)
-57.89M
Diluted EPS (ttm)
-0.8700
Balance Sheet and Cash Flow
Total Cash (mrq)
738k
Total Debt/Equity (mrq)
778.95%
Levered Free Cash Flow (ttm)
10.32M